press1

Proteologics Ltd. announced today entrance into anti-HIV gene therapy feasibility research collaboration with City of Hope National Medical Center, Calif.

15/08/2005

Proteologics Ltd. announced today entrance into anti-HIV gene therapy feasibility research collaboration with City of Hope National Medical Center, Calif.. Both parties will collaborate in the development of innovative gene therapy procedure based on RNA interference (RNAi) directed against the cell's ubiqutin system. The ubiquitin system is involved in maintenance of proteins found within the cell and. Proteologics has identified some components of the ubiquitin system as critical in supporting the HIV lifecycle within infected cells.

Proteologics is focused on ubiquitin ligase target and drug discovery. The company's scientific advisory board is led by Profs. Avram Hershko and Aaron Ciechanover, the 2004 Nobel Prize laureates in chemistry for their discovery of the ubiquitin system. The ubiquitin system is involved in major human diseases including cancer, AIDS, neuro-degeneration and immune disorders. John J. Rossi, Ph.D., chair, Division of Molecular Biology at City of Hope, will develop specific RNAi molecules against ubiquitin targets and measure the impact on HIV replication.

About the technology
RNAi technology is based on a cellular mechanism that controls the expression levels of proteins in the cell. The mechanism was first discovered in the mid '90s. Today the system is being exploited by scientists for silencing specific genes in cells. The silencing is being performed by introduction or expression of small double strand RNA molecules of special structure and specific sequence, which correlates to the targeted gene. Dr. Rossi's technology allows for the selective expression of RNAi molecules solely in HIV infected cells. The purpose of the research collaboration is to develop a method to strengthen AIDS patients' immune systems by "immunizing the cells of immune systems" and making them resistant to HIV.

About City of Hope and Dr Rossi
Founded in 1913, City of Hope is one of the world's leading research and treatment centers for cancer, diabetes, HIV/AIDS, and other life-threatening diseases. City of Hope is a Comprehensive Cancer Center, the highest designation bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network. Named by U.S. News & World Report as one of America's best medical centers for cancer treatment, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. City of Hope's scientific knowledge is shared with medical centers locally and globally, helping patients battling life-threatening diseases around the corner and around the world..

About Proteologics
Proteologics was founded in 1999; it is privately held Delaware Corporation, with R&D performed at its wholly owned Israeli subsidiary, Proteologics, Ltd. To date, the company has raised $29 million from investors including Teva Pharmaceutical Industries Ltd, Concord Ventures (Israel), Reslo Life Sciences Ltd. (Israel), Alex Brown - Deutsche Bank (US), Giza Fund (GE Capital; Israel) and The Challenge Fund (Etgar - Israel).

About the ubiquitin system
The ubiquitin system is involved in a growing list of diseases across many therapeutic areas. These diseases are mainly attributed to the activity of ubiquitin ligases, a class of more than 1,000 highly diverse and specific regulatory enzymes. Proteologics identifies ubiquitin ligases with a causative role in human diseases and subsequently performs drug discovery based on these targets.





Company> \| Overview \| Management \| Scientific advisory board \| Publications \| News
Proteologics Ltd. announced today entrance into anti-HIV gene therapy feasibility research collaboration with City of Hope National Medical Center, Calif. 15/08/2005 Proteologics Ltd. announced today entrance into anti-HIV gene therapy feasibility research collaboration with City of Hope National Medical Center, Calif.. Both parties will collaborate in the development of innovative gene therapy procedure based on RNA interference (RNAi) directed against the cell's ubiqutin system. The ubiquitin system is involved in maintenance of proteins found within the cell and. Proteologics has identified some components of the ubiquitin system as critical in supporting the HIV lifecycle within infected cells. Proteologics is focused on ubiquitin ligase target and drug discovery. The company's scientific advisory board is led by Profs. Avram Hershko and Aaron Ciechanover, the 2004 Nobel Prize laureates in chemistry for their discovery of the ubiquitin system. The ubiquitin system is involved in major human diseases including cancer, AIDS, neuro-degeneration and immune disorders. John J. Rossi, Ph.D., chair, Division of Molecular Biology at City of Hope, will develop specific RNAi molecules against ubiquitin targets and measure the impact on HIV replication. About the technology RNAi technology is based on a cellular mechanism that controls the expression levels of proteins in the cell. The mechanism was first discovered in the mid '90s. Today the system is being exploited by scientists for silencing specific genes in cells. The silencing is being performed by introduction or expression of small double strand RNA molecules of special structure and specific sequence, which correlates to the targeted gene. Dr. Rossi's technology allows for the selective expression of RNAi molecules solely in HIV infected cells. The purpose of the research collaboration is to develop a method to strengthen AIDS patients' immune systems by "immunizing the cells of immune systems" and making them resistant to HIV. About City of Hope and Dr Rossi Founded in 1913, City of Hope is one of the world's leading research and treatment centers for cancer, diabetes, HIV/AIDS, and other life-threatening diseases. City of Hope is a Comprehensive Cancer Center, the highest designation bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network. Named by U.S. News & World Report as one of America's best medical centers for cancer treatment, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. City of Hope's scientific knowledge is shared with medical centers locally and globally, helping patients battling life-threatening diseases around the corner and around the world.. About Proteologics Proteologics was founded in 1999; it is privately held Delaware Corporation, with R&D performed at its wholly owned Israeli subsidiary, Proteologics, Ltd. To date, the company has raised $29 million from investors including Teva Pharmaceutical Industries Ltd, Concord Ventures (Israel), Reslo Life Sciences Ltd. (Israel), Alex Brown - Deutsche Bank (US), Giza Fund (GE Capital; Israel) and The Challenge Fund (Etgar - Israel). About the ubiquitin system The ubiquitin system is involved in a growing list of diseases across many therapeutic areas. These diseases are mainly attributed to the activity of ubiquitin ligases, a class of more than 1,000 highly diverse and specific regulatory enzymes. Proteologics identifies ubiquitin ligases with a causative role in human diseases and subsequently performs drug discovery based on these targets.
	Terms of Use	Site Map